|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
CTD_human |
We investigated the effect of tetrahydroprogesterone on corticotropin-releasing hormone-induced anxiety, the basal and methoxamine-stimulated release of corticotropin-releasing hormone from hypothalamic organ explants in vitro, and adrenalectomy-induced up-regulation of the gene expression of corticotropin-releasing hormone in the hypothalamic paraventricular nucleus in rats.
|
7816204 |
1994 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
CTD_human |
This paper reports the effects on grooming, related behaviors and levels of anxiety induced by the hypophysiotropic peptides corticotropin-releasing hormone (CRH, 1 microgram, 0.2 nmol, icv), thyrotropin-releasing hormone (TRH, 100 micrograms, 275 nmol, icv) and luteinizing hormone-releasing hormone (LHRH, 1.5 micrograms, 1.3 nmol, icv) administered into the lateral ventricle of the brain (icv) of adult male rats of a Holtzman-derived colony (N = 15, each group).
|
8736133 |
1996 |
|
Anxiety Disorders
|
0.400 |
AlteredExpression
|
group |
BEFREE |
This study demonstrates that when applied concomitantly with the stressful challenge, the steroid GABA(A) receptor agonist 3,21-dihydropregnan-20-one (tetrahydrodeoxycorticosterone, THDOC) can attenuate the behavioral and neuroendocrine consequences of repeated maternal separation during early life, e.g., increased anxiety, an exaggerated adrenocortical secretory response to stress, impaired responsiveness to glucocorticoid feedback, and altered transcription of the genes encoding corticotropin-releasing hormone (CRH) in the hypothalamus and glucocorticoid receptors in the hippocampus.
|
9062354 |
1997 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
These data indicate that CRF receptor antagonists may be useful for the treatment of the disease states where CRF is elevated such as anxiety and depression, anorexia nervosa and stroke and that ligand inhibitors of CRF-BP may be used to elevate brain levels of 'free' urocortin and other CRF-related peptides.
|
9118350 |
1996 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Expression of oncogene sequences in gonadotropin-releasing hormone neurons has allowed the development of cell lines from the resulting tumors, overproduction of corticotropin-releasing factor has produced animal models of anxiety and obesity, and directed ectopic expression of growth hormone has generated a potentially useful rat model of dwarfism.
|
9535288 |
1998 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
CTD_human |
The Y1 receptor antagonist blocked the anxiolytic-like effect of neuropeptide Y, while the Y2 receptor antagonist was ineffective.We conclude that neuropeptide Y in the dorsocaudal lateral septum may act as an endogenous anxiolytic and antagonize corticotropin-releasing hormone (stress)-induced anxiety.
|
11440811 |
2001 |
|
Anxiety Disorders
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Both HPA axis activity and anxiety are modulated by corticotropin releasing hormone (CRH); therefore, we include in the discussion results obtained with genetically modified CRH or CRH receptor mice.
|
11827739 |
2002 |
|
Anxiety Disorders
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Levels of corticotropin-releasing hormone are elevated in patients with depression and anxiety and are expected to be elevated in patients with congenital adrenal hyperplasia; it is unknown whether patients with 21-hydroxylase deficiency have an increased incidence of these psychiatric disorders.
|
11848730 |
2002 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
CTD_human |
These results suggest that the onset of r/hCRF and rUcn actions related to behavioral responses to anxiety is likely to depend on brain peptide-specific mechanisms including binding properties to CRF-receptors, differential distribution to specific functional brain sites and the distribution and effectiveness of binding-protein interactions.
|
11875628 |
2002 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
CTD_human |
Quantifying fear potentiated startle using absolute versus proportional increase scoring methods: implications for the neurocircuitry of fear and anxiety.
|
12424556 |
2002 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
CTD_human |
CRF elicited a wide range of behaviors, which fell into three broad categories: anxiety-like, depressive-like, and externally oriented.
|
12438692 |
2002 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
CTD_human |
Taken with the evidence for hypersecretion of CRF in patients with depression and anxiety-related disorders, our findings lead to the intriguing hypothesis that interaction between CRF and 5-HT, especially in the ventral hippocampus, plays a role in the etiology of affective and anxiety disorders.
|
14575894 |
2003 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Given the fundamental role of the corticotropin-releasing hormone (CRH) system in anxiety, stress-associated pathologies, and mood disorders, we describe genetic modifications of the genes that encode proteins integral to the CRH/CRH receptor system with particular emphasis on conditional gene-targeting strategies.
|
14755129 |
2004 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Because both cortisol and CRH have behavioral effects, and hypothalamic CRH hypersecretion has been associated with chronic states of anxiety and depression, we performed endocrine and psychologic studies in consecutively admitted parents of patients with classic congenital adrenal hyperplasia due to 21-OH deficiency and parents of children with other chronic endocrine disorders.
|
15126546 |
2004 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Two subtypes of the corticotropin-releasing factor (CRF) receptor, CRF(1) and CRF(2), differentially modulate brain functions such as anxiety and memory.
|
15192151 |
2004 |
|
Anxiety Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
A large body of preclinical and clinical evidence points to a key role of the corticotropin-releasing hormone (CRH) receptor 1 subtype (CRHR1) in mediating CRH-elicited effects in anxiety, depressive disorders and stress-associated pathologies.
|
15310462 |
2004 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Genetic modifications of the CRH system by conventional and conditional gene targeting strategies in the mouse allowed us to study the endogenous mechanisms underlying HPA system regulation and CRH-related neuronal circuitries involved in pathways mediating anxiety and stress-related behaviour.
|
15771006 |
2005 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
CTD_human |
CRF also increased anxiety/fear-like behaviors in the forced swim and predator odor tests.
|
16495007 |
2006 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Corticotropin-releasing factor, vasopressin and receptor systems in depression and anxiety.
|
16733617 |
2006 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Corticotropin-releasing hormone (CRH) has been implicated in the pathophysiology of anxiety disorders and depression.
|
16884458 |
2006 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
CTD_human |
Restraint-induced corticosterone secretion and hypothalamic CRH mRNA expression are augmented during acute withdrawal from chronic cocaine administration.
|
17293045 |
2007 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
A concatenation of findings from preclinical and clinical studies support a preeminent function for the corticotropin-releasing factor (CRF) system in mediating the physiological response to external stressors and in the pathophysiology of anxiety and depression.
|
20010888 |
2010 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
The corticotropin-releasing factor (CRF, or corticotropin-releasing hormone) and arginine vasopressin systems have been implicated in the pathophysiology of anxiety and depressive disorders and response to antidepressant treatment.
|
20368512 |
2010 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
CRF receptor 1 regulates anxiety behavior via sensitization of 5-HT2 receptor signaling.
|
20383137 |
2010 |
|
Anxiety Disorders
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Corticotropin-releasing factor (CRF) has a key role in the central stress response, and altered levels of this neuropeptide are linked to stress-related psychopathologies such as anxiety and depression.
|
20548294 |
2011 |